Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 7680 results

  1. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued [GID-TA10171]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued [GID-TA10110]

    Technology appraisal guidance
    Discontinued

  3. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  4. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued [GID-TA10697]

    Technology appraisal guidance
    Discontinued

  6. Peramivir for treating influenza [ID828]

    Discontinued [GID-TA10155]

    Technology appraisal guidance
    Discontinued

  7. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued [GID-TA10395]

    Technology appraisal guidance
    Discontinued

  8. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    In development [GID-TA10185] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

    Discontinued [GID-TA10442]

    Technology appraisal guidance
    Discontinued

  10. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued [GID-TAG422]

    Technology appraisal guidance
    Discontinued

  11. Workplace health for employees with disabilities and long-term conditions

    Discontinued [GID-PHG58]

    NICE guideline
    Discontinued

  12. Inpatient mental health settings

    Discontinued [GID-SGWAVE0701]

    Safe staffing guideline
    Discontinued

  13. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued [GID-TA10154]

    Technology appraisal guidance
    Discontinued

  14. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  15. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued [GID-TA10179]

    Technology appraisal guidance
    Discontinued